Related Experiment Video

Updated: Mar 19, 2026

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors
12:40

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors

Published on: December 7, 2014

15.3K

Synthetic Lethal Screen Demonstrates That a JAK2 Inhibitor Suppresses a BCL6-dependent IL10RA/JAK2/STAT3 Pathway in

Daniel Beck1, Jenny Zobel2, Ruth Barber3

  • 1From the Department of Cancer Studies, Ernest and Helen Scott Haematology Research Institute, and.

The Journal of Biological Chemistry
|June 9, 2016
PubMed

Insights

Synthetic lethal screening identified a BCL6-repressed survival pathway involving IL10RA/JAK2/STAT3 in lymphoma. JAK2 inhibitors may benefit specific diffuse large B-cell lymphoma subtypes.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • The BCL6 proto-oncogene plays a critical role in lymphoma pathogenesis.
  • Identifying BCL6-dependent survival pathways is crucial for developing targeted therapies.

Purpose of the Study:

  • To identify survival pathways suppressed by BCL6 in lymphoma using synthetic lethal screening.
  • To explore the therapeutic potential of targeting identified pathways in BCL6-deficient lymphoma.

Main Methods:

  • Utilized a conditionally BCL6-deficient Burkitt lymphoma cell line (DG75-AB7) for synthetic lethal screening with small molecules.
  • Investigated the expression of JAK2, IL10RA, and STAT3 signaling components.
  • Performed in vitro BCL6 promoter binding assays and ChIP-seq to confirm JAK2 as a direct target gene.

Main Results:

  • Lestaurtinib, a JAK2 inhibitor, repressed survival of BCL6-deficient cells in vitro and reduced tumor growth in vivo.
  • BCL6 deficiency led to increased JAK2 expression and STAT3 phosphorylation.
  • IL10 receptor A (IL10RA) blockade reduced STAT3 phosphorylation, defining an IL10RA/JAK2/STAT3 pathway repressed by BCL6.
  • JAK2 was identified as a direct BCL6 target gene.

Conclusions:

  • BCL6 represses the IL10RA/JAK2/STAT3 survival pathway in lymphoma.
  • JAK2 inhibitors represent a potential therapeutic strategy, particularly for poor-prognosis ABC-DLBCL with high IL10RA, JAK2, and STAT3 expression.
  • Combination therapy with IL10RA inhibitors may enhance treatment efficacy.
Keywords:
Janus kinase (JAK)interleukinlymphocytelymphomasignaling

More Related Videos

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries08:49

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries

Published on: January 22, 2019

9.6K
Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence10:09

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence

Published on: January 7, 2019

8.8K

Related Concept Videos

The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
13.7K
The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
9.1K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.1K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
6.2K
B Cell Activation and Differentiation01:24

B Cell Activation and Differentiation

The adaptive immune response, a sophisticated defense mechanism, relies on the activation and differentiation of B lymphocytes, or B cells. These processes enable our bodies to mount a tailored response against specific pathogens such as bacteria, free virus particles, toxins, and parasites.
When naive B cells encounter a specific antigen that can bind to the B cell receptor (BCR) on their surface, they undergo sensitization to respond to the antigen's presence. Sensitization begins with...
17.8K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
6.1K